Joseph Belanoff Sells 26,198 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Key Points

• CEO Joseph Belanoff sold 26,198 shares on March 25 at an average price of $50.07 for a total of $1.312 million, trimming his stake by 0.89% while still holding 2,918,326 shares valued at about $146.1 million.
• FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer is the primary catalyst behind a recent sharp rally, prompting broker upgrades and heavy trading volume that have driven large intraday price swings.
• Despite the rally, Corcept missed quarterly EPS and revenue estimates and faces multiple shareholder lawsuits and recent insider selling, creating legal and sentiment risks even as institutional ownership remains high and analysts show a mixed but overall "Moderate Buy" stance.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) CEO Joseph Belanoff sold 26,198 shares of the stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total value of $1,311,733.86. Following the sale, the chief executive officer directly owned 2,918,326 shares in the company, valued at $146,120,582.82. This trade represents a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $37.60 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The firm has a market cap of $4.00 billion, a price-to-earnings ratio of 45.85 and a beta of 0.29. The business has a 50-day simple moving average of $37.53 and a two-hundred day simple moving average of $60.76. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $117.33.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The company had revenue of $202.13 million for the quarter, compared to analysts' expectations of $254.94 million. During the same period in the previous year, the business earned $0.26 EPS. The business's revenue was up 11.1% compared to the same quarter last year. On average, analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer is a material commercial catalyst that triggered the earlier sharp rally; approval creates a new revenue pathway and is the primary reason investors re‑rated the stock this week. FDA approval report
• Positive Sentiment: Broker/analyst support: Wolfe Research upgraded CORT (from underperform to peer‑perform) and other brokers (Truist, Canaccord) have issued bullish/strong‑buy views or raised targets, which can sustain buying interest as the market models new sales upside. Wolfe Research upgrade
• Neutral Sentiment: Market structure/volatility: trading halts and large intraday prints accompanied the approval-driven move — expect continued high volume and price swings as investors reprice expectations for launch and uptake. Market reaction coverage
• Neutral Sentiment: Consensus/ratings mix: some outlets show a "moderate buy" brokerage consensus; analysts remain mixed on valuation as the market weighs launch potential vs. prior execution and study data. Broker consensus report
• Negative Sentiment: Legal risk: multiple law firms have filed shareholder alerts and class actions alleging that Corcept misled investors about regulatory issues and patent matters; these suits (and the referenced FDA rejection / federal court patent loss claims) create potential liability, discovery risk and distraction for management. Hagens Berman class‑action alert
• Negative Sentiment: Insider selling: a recent disclosed sale by an insider reduced holdings significantly; while not proof of negative outlook, such sales can weigh on sentiment when paired with litigation headlines. Insider sale filing
• Negative Sentiment: Analyst divergence / forecast cuts: some firms have tempered long‑term estimates or issued cautious notes (e.g., a pessimistic forecast from HC Wainwright in recent coverage), underscoring uncertainty around peak sales and reimbursement. HC Wainwright coverage

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on CORT shares. Zacks Research downgraded shares of Corcept Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, January 13th. Wolfe Research raised Corcept Therapeutics from an "underperform" rating to a "peer perform" rating in a report on Thursday. Weiss Ratings restated a "hold (c)" rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. HC Wainwright cut their price objective on Corcept Therapeutics from $67.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Truist Financial upgraded Corcept Therapeutics to a "strong-buy" rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $77.67.

Institutional Trading of Corcept Therapeutics

Several large investors have recently added to or reduced their stakes in CORT. State Street Corp increased its holdings in Corcept Therapeutics by 0.5% during the fourth quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company's stock valued at $103,915,000 after buying an additional 15,656 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Corcept Therapeutics by 38.0% during the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company's stock worth $92,892,000 after acquiring an additional 734,646 shares during the last quarter. Morgan Stanley boosted its stake in shares of Corcept Therapeutics by 34.1% during the 4th quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company's stock worth $55,404,000 after acquiring an additional 405,081 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Corcept Therapeutics by 546.9% during the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company's stock valued at $125,264,000 after acquiring an additional 1,274,215 shares during the period. Finally, TD Asset Management Inc grew its position in shares of Corcept Therapeutics by 4.0% during the 4th quarter. TD Asset Management Inc now owns 994,844 shares of the biotechnology company's stock valued at $34,621,000 after acquiring an additional 38,708 shares during the period. 93.61% of the stock is currently owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.